Anglo Scientific EIS Fund

Innvotec’s flagship Fund ‘Anglo Scientific EIS’ has an impressive portfolio of innovative technology companies, each underpinned by groundbreaking science. Led by successful technology entrepreneurs, these EIS qualifying companies are developing and delivering disruptive products and systems to address identified, significant market opportunities in healthcare, security & communications. 

The Anglo Scientific EIS funds are managed in conjunction with our Strategic Partner Anglo Scientific Limited. Since being launched in 2009, the Fund’s portfolio has grown, with an increasing number of companies and at a range of maturities - from start-up to those already generating revenue. Therefore,  investors get a balanced portfolio with shorter potential timeframes to first exits, without compromising the opportunity for substantial gains later. In advance of any commitment, Investors in AS EIS funds are informed about the companies that will make up their portfolio; we believe this feature is a crucial differentiator for the Fund.

In 2016, the first company, specialising in the treatment of dysphagia (an inability to swallow typically resulting from a stroke) ‘exited’ the Anglo Scientific portfolio via a very profitable exit to Nestle. Phagenesis Exit Case Study.

Like all Innvotec-managed Funds, AS EIS has an evergreen status, with commitment being invested quarterly and on the regular quarter days or shortly thereafter, which means investors commitment is invested inside three months, which, in turn, means timely receipt of HMRC certificates. In the run-up to the tax year end, latecomers can invest up to the last working day before 5 April.

For more details, please download the documents* available on this page.

Anglo Scientific EIS Overview & FAQs

Anglo Scientific EIS Fund Performance Report - December 2017

Anglo Scientific EIS Application Pack 2017-18

Anglo Scientific EIS Fund Executive Summary

Anglo Scientific EIS Fund Portfolio & Performance - 2017

Anglo Scientific EIS Allenbridge IQ Publication

Anglo Scientific KID (Key Information Document)

*PLEASE NOTE: These Fund documents are only for Applicable Investors defined as (1) professional clients, (2) retail clients who confirm that in relation to an investment in the Fund they have received regulated investment advice or investment management services from an authorised person, (3) retail clients who are venture capital or corporate finance contacts (4) retail clients who self-certify or are certified as sophisticated investors, (5) retail clients who are certified as high net worth investors or (6) retail clients who certify that they have not invested and will not invest more than 10% of their net investible assets in non-readily realisable securities.
These documents may not be distributed without the agreement of Innvotec and/or may only be distributed in compliance with the FSMA and the rules of the FCA. 

Watch this video to learn more about the Anglo Scientific EIS fund.

"I invested in the Innvotec SEIS fund in 2013 and have been delighted with its performance over the past 4 years. Having got to know John M and the team who manage Innvotec, I find them approachable, responsive and full of integrity with an exceptional pre-investment approach. As an adjunct, I have also taken up an investor/mentor role with one of the invested FinTech businesses, which is incredibly stimulating and fulfilling. "
"I had been disappointed by the returns available through the conventional share investments – and more recently by the widely varying performance of VCTs. Investing through an SEIS/EIS hybrid fund provides access to both types of such businesses – and also ensures that the full tax advantages of such investment are maximised. I was attracted to Innvotec as a fund manager, both by virtue of its excellent track record in both EIS and SEIS funds, and the fact that its charges among are amongst the lowest in the sector. "
"As a retired plc director I had some knowledge of investment, but being relatively new to such early-stage businesses, I was also concerned about risk. The OION fund was therefore an ideal way to spread this risk across multiple businesses and sectors and still enjoy the exceptional levels of tax relief. In the first semi-annual report I was delighted to see the progress which of the achieved within the fund - and will be including the new hybrid fund within my investment portfolio for this tax year."
"As a retired city lawyer, I was looking for a tax efficient – but hands off – scheme which would enable me to achieve both deductibility at the point of investment, and avoidance of capital gains. I was also attracted to the opportunity to support and back emerging enterprises from their earliest stages. Fund administration and communication by Innvotec have been to a particularly high standard; compliance with HMRC rules is straightforward, and as part of a broader investment portfolio, managed SEIS funds have an important role to play. "
"As an architect running a busy partnership, I was looking for a way of investing within a scheme which offered both high potential growth, and commensurate tax efficiency. Innvotec – with one of the longest track records within its sector, and a consistent and high level published returns – seemed an immediate and obvious choice. "
"Together with colleagues, I have introduced a number of private clients to the Innvotec managed funds. A key element of our selection criteria is transparency. Both ourselves and our clients appreciate a firm whose product charging really does favour the private investor. We have become accustomed to good performance, a highly professional team and quality of service."

© Copyright 2017, Innvotec Ltd. All rights reserved.
Privacy Policy | Accessibility Statement | Website Design
Innvotec is authorised and regulated by the Financial Conduct Authority (FCA) – FRN 122365

Innvotec Limited is a registered company in England & Wales. Registration Number: 02030086. Registered Office: Amelia House, Crescent Road, Worthing, England, BN11 1QR. *This is not our contact address. For the contact address please click here*